Overview

Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
A multicenter, single-arm clinical study of evaluate the efficacy and safety of selinexor combined with venetoclax as maintenance therapy following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients.
Phase:
PHASE2
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
selinexor
venetoclax